OncoGenex shares fall after release of prostate cancer study data

OncoGenex Pharmaceuticals Inc. shares dropped in the extended session Tuesday following a brief halt after the tiny biotech said some patients in its prostate cancer drug study did not respond to treatment. OncoGenex shares fell 29% to $1.85. The company said a subpopulation with an aggressive form of prostate cancer in its late-stage study for Custirsen did not show a significant improvement in survival when combined with cancer drug cabazitaxel, compared to cabazitaxel alone.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.